Document is current
Any future updates will be listed below
-
Authors
Pouw, J. E. E. https://orcid.org/0000-0003-1358-1804
Stavenga, M.
Wijngaarden, J. E.
Oprea-Lager, D. E.
Schober, P.
Schuit, R. C.
van Eeden, S. P. P.
Windhorst, A. D.
Murillo, M. M.
Galette, P.
Parker, C. A.
Bonasera, T. A.
de Gruijl, T. D.
Yaqub, M. M.
Menke-van der Houven van Oordt Oord, C. W.
Boellaard, R.
- License Information
-
More Information
Article History
Received: 2 January 2026
Accepted: 4 August 2026
First Online: 6 October 2026
Declarations
Ethics approval and consent to participate: This study was performed in line with the principles of the Declaration of Helsinki and approved by the institutional review board of the Amsterdam UMC. Informed consent for study participation was obtained from all individual patients included in the study.
Consent for publication: Not applicable.
Competing interests: JEEP became employee and stockholder at GSK during the manuscript revision process. MMM, PG † , CAP † and TAB † are (former † ) employees and stockholders of GSK. PG is currently employed by Pfizer and TAB by Perceptive. ADW is editor-in-chief of Nuclear Medicine & Biology. CWMvdHvO received institutional funding from BI, GSK, BMS, AstraZeneca, Pfizer and consulted for GEHealthcare, Eli-Lilly. TDdG holds stocks from LAVA-therapeutics and is scientific advisor for GE Healthcare, LAVA-therapeutics, Mendus, and Vivaldi therapeutics. Cellsight Technologies has reviewed and provided comments on the manuscript.
